Form 8-K - Current report:
SEC Accession No. 0001213900-24-076565
Filing Date
2024-09-06
Accepted
2024-09-06 16:43:45
Documents
13
Period of Report
2024-09-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0213833-8k_elevailabs.htm   iXBRL 8-K 28922
  Complete submission text file 0001213900-24-076565.txt   205600

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE elab-20240904.xsd EX-101.SCH 3033
3 XBRL LABEL FILE elab-20240904_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE elab-20240904_pre.xml EX-101.PRE 22371
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0213833-8k_elevailabs_htm.xml XML 3795
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241285020
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)